Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence and factors associated with symptom persistence: A prospective study of 429 mild COVID-19 outpatients.
Faycal A, Ndoadoumgue AL, Sellem B, Blanc C, Dudoit Y, Schneider L, Tubiana R, Valantin MA, Seang S, Palich R, Bleibtreu A, Monsel G, Godefroy N, Itani O, Paccoud O, Pourcher V, Caumes E, Ktorza N, Chermak A, Abdi B, Assoumou L, Katlama C; COVIDOM-19 PSL research group. Faycal A, et al. Among authors: ktorza n. Infect Dis Now. 2022 Mar;52(2):75-81. doi: 10.1016/j.idnow.2021.11.003. Epub 2021 Nov 17. Infect Dis Now. 2022. PMID: 34800742 Free PMC article.
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
Wirden M, Delaugerre C, Marcelin AG, Ktorza N, Ait Mohand H, Dominguez S, Schneider L, Ghosn J, Pauchard M, Costagliola D, Katlama C, Calvez V. Wirden M, et al. Among authors: ktorza n. Antimicrob Agents Chemother. 2004 Feb;48(2):644-7. doi: 10.1128/AAC.48.2.644-647.2004. Antimicrob Agents Chemother. 2004. PMID: 14742228 Free PMC article. Clinical Trial.
Pitfalls of HIV genotypic tropism testing after treatment interruption.
Wirden M, Soulié C, Fourati S, Valantin MA, Simon A, Ktorza N, Tubiana R, Bonmarchand M, Schneider L, Calvez V, Katlama C, Marcelin AG. Wirden M, et al. Among authors: ktorza n. J Antimicrob Chemother. 2013 Jan;68(1):188-9. doi: 10.1093/jac/dks362. Epub 2012 Sep 6. J Antimicrob Chemother. 2013. PMID: 22954492
Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
Schneider L, Ktorza N, Fourati S, Assoumou L, Courbon E, Caby F, Blanc C, Tindel M, Agher R, Marcelin AG, Calvez V, Peytavin G, Katlama C. Schneider L, et al. Among authors: ktorza n. HIV Clin Trials. 2012 Sep-Oct;13(5):284-8. doi: 10.1310/hct1305-284. HIV Clin Trials. 2012. PMID: 23134629 Clinical Trial.
Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies.
Todesco E, Sayon S, Fourati S, Tubiana R, Simon A, Ktorza N, Schneider L, Peytavin G, Malet I, Van den Eede P, Katlama C, Calvez V, Marcelin AG, Wirden M. Todesco E, et al. Among authors: ktorza n. J Antimicrob Chemother. 2013 Dec;68(12):2882-9. doi: 10.1093/jac/dkt272. Epub 2013 Jul 19. J Antimicrob Chemother. 2013. PMID: 23873645
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Clinical Trial.
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.
Sempere A, Assoumou L, González-Cordón A, Waters L, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell J, Pozniak A, Martínez E; NEAT 022 Study Group. Sempere A, et al. Clin Infect Dis. 2023 Oct 5;77(7):991-1009. doi: 10.1093/cid/ciad297. Clin Infect Dis. 2023. PMID: 37207617
21 results